drugset / Trial / NCT03757403

RDD1609 as a Treatment for Idiopathic Pruritus Ani

NCT03757403

Phase 2 Withdrawn RDD Pharma Ltd
RandomizedCrossoverTriple-blindTreatment

Summary

This is a double-blind, randomized, placebo-controlled, crossover trial, to test the hypothesis that RDD1609 is effective in treating idiopathic pruritus ani.

Timeline

Start
2020-05-01
Primary completion
2020-11-30
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject RDD1609 Unknown Topical
Background Mebendazole Small molecule 100 mg

Indications

No indication recorded.